ITRM Iterum Therapeutics plc

Nasdaq iterumtx.com


$ 0.70 $ -0.04 (-5.01 %)    

Wednesday, 22-Oct-2025 15:59:50 EDT
QQQ $ 605.35 $ -5.89 (-0.96 %)
DIA $ 465.12 $ -3.44 (-0.73 %)
SPY $ 667.63 $ -3.49 (-0.52 %)
TLT $ 92.17 $ 0.06 (0.07 %)
GLD $ 377.47 $ 0.04 (0.01 %)
$ 0.6971
$ 0.72
$ 0.69 x 780
$ 0.79 x 599
$ 0.69 - $ 0.74
$ 0.61 - $ 3.02
601,890
na
31.13M
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 02-07-2025 12-31-2024 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-28-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-12-2022 06-30-2022 10-Q
14 05-13-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-13-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-12-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-06-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-12-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-14-2019 06-30-2019 10-Q
26 05-14-2019 03-31-2019 10-Q
27 03-25-2019 12-31-2018 10-K
28 11-14-2018 09-30-2018 10-Q
29 08-14-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 iterum-therapeutics-announces-us-commercial-launch-of-orlynvah-oral-tablets

Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infecti...

 correction-iterum-therapeutics-q2-adj-eps-013-misses-011-estimate-cash-and-equivalents-of-13m-runway-into-2026

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of...

 iterum-shares-phase-3-trial-results-showing-how-its-oral-antibiotic-compares-to-augmentin-for-utis

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generat...

Core News & Articles

Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generat...

 iterum-therapeutics-q1-adj-eps-010-beats-014-estimate

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $...

 hc-wainwright--co-assumes-iterum-therapeutics-at-buy-announces-price-target-of-9

HC Wainwright & Co. analyst Joseph Pantginis assumes Iterum Therapeutics (NASDAQ:ITRM) with a Buy rating and announces P...

 iterum-therapeutics-announces-that-one-poster-was-presented-on-impact-of-age-on-antibiotic-resistance-and-efficacy-of-antibiotics-for-women-with-uncomplicated-urinary-tract-infection-at-the-35th-annual-european-congress-of-clinical-microbiology-and-infectious-disease-in-vienna-austria-from-april-11-15-2025

DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering n...

 iterum-therapeutics-files-for-mixed-shelf-of-up-to-150m

- SEC Filing

 wall-street-drops-on-tariffs-threat-dollar-rises-uber-rockets-on-ackmans-tweet-whats-driving-markets-friday

Wall Street slumped into negative territory late in the week as renewed fears over inflation and trade tariffs eroded risk appe...

 iterum-therapeutics-q4-2024-adj-eps-012-beats-021-estimate

Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION